David Curiel

Using antibodies from camels and alpacas, scientists led by David T. Curiel, MD, PhD, at Washington University School of Medicine in St. Louis have found a way to deliver anticancer viruses directly to tumor cells, leaving other types of cells uninfected. The discovery may solve a longstanding problem in the field of gene therapy.

Working in mice, School of Medicine researchers report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene of interest that can be injected into the bloodstream and make its way to the right cells. In this proof-of-concept study, they targeted tumor blood vessels in mice without affecting healthy tissues.

Five scientists at Washington University School of Medicine in St. Louis have received a combined $2 million in grants for their innovative approaches to fighting cancer. The awards are from the Alvin J. Siteman Cancer Research Fund.

Researchers at Washington University School of Medicine in St. Louis have received a $3 million grant from the National Cancer Institute (NCI) to develop a triple threat in the fight against cancer: a single virus equipped to find, image and kill cancer cells, all at once.

Washington University School of Medicine in St. Louis has launched a new center devoted to turning innovations developed in the laboratory into improved treatments at the patient’s bedside. Led by David T. Curiel, MD, PhD, the Biologic Therapeutics Center will foster translational medicine and support a quicker transition of knowledge from the lab to the clinic.